Gal Finer

912 citations
19 papers · 610 indexed · h-index 11
Topics
Biomedical Research and Pathophysiology (4 papers)Renal cell carcinoma treatment (3 papers)Renal and related cancers (3 papers)
Partner nations
United StatesIsraelJapan

In The Last Decade

Gal Finer

19 papers receiving 597 citations

Peers

Gal Finer
Comparison fields: 5 of 91
  • Molecular Biology 346
  • Pulmonary and Respiratory Medicine 103
  • Nephrology 102
  • Epidemiology 100
  • Pediatrics, Perinatology and Child Health 71
Replace F. Mollica with:
F. Mollica Italy
Burcu Öztürk Hişmi Türkiye
Angela Robbiano Italy
G Malpuech France
Can Liao China
Karen Chong Canada
Tadafumi Yokoyama Japan
Osnat Admoni Israel
Jacques Simon Belgium
Tomonori Harada Japan
Gal Finer relative to F. Mollica Italy F. Mollica's profile →
Citations per field
00.5×6.5×
F. Mollica · 1×
Citations per year

Countries citing papers authored by Gal Finer

Since Specialization
Citations

This map shows the geographic impact of Gal Finer's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Gal Finer with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Gal Finer more than expected).

Fields of papers citing papers by Gal Finer

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Gal Finer. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Gal Finer. The network helps show where Gal Finer may publish in the future.

Co-authorship network of co-authors of Gal Finer

This figure shows the co-authorship network connecting the top 25 collaborators of Gal Finer. A scholar is included among the top collaborators of Gal Finer based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Gal Finer. Gal Finer is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

19 of 19 papers shown
#WorkIndexed citations
1 1
2 5
3 3
4 7
5 17
6 7
7 3
8 29
9 41
10 18
11 11
12 137
13 92
14 64
15 6
16 89
17
[Genetic and phenotypic aspects of autosomal recessive polycystic kidney disease in southern Israel].
1
18 67
19 12

About Gal Finer

Gal Finer is a scholar working on Nephrology, Urology and Pathology and Forensic Medicine, having authored 19 papers that have together received 610 indexed citations. Recurring topics across this work include Biomedical Research and Pathophysiology (4 papers), Renal cell carcinoma treatment (3 papers) and Renal and related cancers (3 papers). The work is most often cited by research in Nephrology (102 citations), Clinical Biochemistry (60 citations) and Urology (42 citations). Gal Finer has collaborated with scholars based in United States, Israel and Japan. Frequent co-authors include Daniel Landau, Ohad S. Birk, Rivka Ofir, Zamir Shorer, Ortal Barel, Craig B. Langman, Stavit A. Shalev, Noam Zilberberg, Joël Zlotogora and Hanna Shalev. Their work appears in journals such as Nature Genetics, Kidney International and Journal of the American Society of Nephrology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026